Background This study advances the clinical development of the RTS, S/AS01B candidate
malaria vaccine to malaria endemic populations. As a primary objective it compares the …

Background We previously reported that the RTS, S/AS02A vaccine had an acceptable
safety profile, was immunogenic, and demonstrated efficacy against Plasmodium falciparum …

The first clinical Phase III trial evaluating a malaria vaccine was completed in December
2013 at 11 sites from seven sub-Saharan African countries. This systematic review assesses …

The malaria vaccine candidate, RTS, S/AS01E, showed promising protective efficacy in a
trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the …

Background The candidate malaria vaccine RTS, S/AS01E has entered phase 3 trials, but
data on long-term outcomes are limited. Methods For 4 years, we followed children who had …

RTS, S is the most advanced candidate vaccine against human malaria. During its
remarkable journey from conception and design in the early 1980s to the multicenter Phase …

Introduction Mass malaria vaccination, rather than vaccinating only children below age 5,
has been proven to have the potential to reduce morbidity and mortality among those …

Abstract Background In 2019, the RTS, S/AS01E malaria vaccine was introduced on a pilot
basis in six regions of Ghana by the Ministry of Health/Ghana Health Service as part of the …

We conducted a phase 1 trial of candidate malaria vaccine RTS, S/AS02A in western Kenya
to determine its safety and immunogenicity in healthy adults in an area hyperendemic for …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …